[go: up one dir, main page]

WO2007009191A8 - Method for treating cancer - Google Patents

Method for treating cancer

Info

Publication number
WO2007009191A8
WO2007009191A8 PCT/AU2006/001033 AU2006001033W WO2007009191A8 WO 2007009191 A8 WO2007009191 A8 WO 2007009191A8 AU 2006001033 W AU2006001033 W AU 2006001033W WO 2007009191 A8 WO2007009191 A8 WO 2007009191A8
Authority
WO
WIPO (PCT)
Prior art keywords
metastatic cancer
cancer
killing
kits
treating cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU2006/001033
Other languages
French (fr)
Other versions
WO2007009191A1 (en
Inventor
Barry John Allen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NewSouth Innovations Pty Ltd
Original Assignee
NewSouth Innovations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005903890A external-priority patent/AU2005903890A0/en
Application filed by NewSouth Innovations Pty Ltd filed Critical NewSouth Innovations Pty Ltd
Priority to AU2006272372A priority Critical patent/AU2006272372A1/en
Priority to JP2008521751A priority patent/JP2009501731A/en
Priority to EP06760894A priority patent/EP1909854A4/en
Priority to US11/996,270 priority patent/US20090311174A1/en
Publication of WO2007009191A1 publication Critical patent/WO2007009191A1/en
Publication of WO2007009191A8 publication Critical patent/WO2007009191A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1066—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to methods, kits, compositions and uses thereof for treating cancer. In particular, the present invention relates to methods, kits, compositions and uses thereof for the treatment of metastatic cancer, the treatment of angiogenesis associated with metastatic cancer, inhibiting formation of vasculature associated with metastatic cancer, killing pericytes associated with metastatic cancer and killing cancer cells contiguous with tumour capillaries associated with metastatic cancer, comprising a killing agent conjugated to a protein, and wherein said killing agent conjugated to said protein binds to at least one cell associated with the metastatic cancer.
PCT/AU2006/001033 2005-07-21 2006-07-21 Method for treating cancer Ceased WO2007009191A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2006272372A AU2006272372A1 (en) 2005-07-21 2006-07-21 Method for treating cancer
JP2008521751A JP2009501731A (en) 2005-07-21 2006-07-21 How to treat cancer
EP06760894A EP1909854A4 (en) 2005-07-21 2006-07-21 Method for treating cancer
US11/996,270 US20090311174A1 (en) 2005-07-21 2006-07-21 Method For Treating Cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2005903890A AU2005903890A0 (en) 2005-07-21 Method for treating cancer
AU2005903890 2005-07-21

Publications (2)

Publication Number Publication Date
WO2007009191A1 WO2007009191A1 (en) 2007-01-25
WO2007009191A8 true WO2007009191A8 (en) 2007-08-16

Family

ID=37668362

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2006/001033 Ceased WO2007009191A1 (en) 2005-07-21 2006-07-21 Method for treating cancer

Country Status (5)

Country Link
US (1) US20090311174A1 (en)
EP (1) EP1909854A4 (en)
JP (1) JP2009501731A (en)
KR (1) KR20080097382A (en)
WO (1) WO2007009191A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008013912A1 (en) 2006-07-28 2008-01-31 Novartis Ag Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma
DK2118123T3 (en) * 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
KR101623985B1 (en) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Stitched polypeptides
US8318162B2 (en) 2009-07-16 2012-11-27 Xoma Technology Ltd. Antibodies to high molecular weight melanoma associated antigen
DK2603600T3 (en) 2010-08-13 2019-03-04 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES
BR112014009418A2 (en) 2011-10-18 2017-04-18 Aileron Therapeutics Inc peptidomimetic macrocycles
CN112500466B (en) 2012-02-15 2022-05-03 艾瑞朗医疗公司 Peptidomimetic macrocycles
HK1205454A1 (en) * 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
CA2961258A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
MX389354B (en) 2014-09-24 2025-03-20 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF.
US9433690B1 (en) * 2015-02-26 2016-09-06 Sciencons AS Radiopharmaceutical solutions with advantageous properties
CA2979847A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
AUPQ582400A0 (en) * 2000-02-24 2000-03-16 Biotech Australia Pty Limited A method of treatment and agents for use therein
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP

Also Published As

Publication number Publication date
WO2007009191A1 (en) 2007-01-25
EP1909854A4 (en) 2012-02-22
EP1909854A1 (en) 2008-04-16
JP2009501731A (en) 2009-01-22
KR20080097382A (en) 2008-11-05
US20090311174A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
WO2007053648A3 (en) Compositions and methods for treating and diagnosing cancer
WO2007126799A3 (en) Compositions and methods of use for antibodies of c-met
WO2007009191A8 (en) Method for treating cancer
WO2008022295A3 (en) Prlr-specific antibody and uses thereof
WO2006003388A8 (en) Compositions and methods for treating inflammatory disorders
WO2005005601A3 (en) Compositions and methods for treating and diagnosing cancer
WO2008094708A3 (en) Activin-actriia antagonists and uses for treating or preventing breast cancer
WO2006036922A3 (en) Srage mimetibody, compositions, methods and uses
WO2004080418A3 (en) Nucleic acid compounds for inhibiting angiogenesis and tumor growth
WO2009006577A3 (en) Compositions and methods for inhibiting ezh2
WO2008036419A3 (en) Aldehyde dehydrogenase 1(aldh1) as a cancer stem cell marker
WO2006135886A3 (en) Compositions and methods for treating and diagnosing cancer
WO2007067991A3 (en) Human monoclonal antibodies to o8e
WO2007002223A3 (en) Cd19 antibodies and their uses
WO2009064486A3 (en) Inhibitors of pim protein kinases, compositions, and methods for treating cancer
WO2007000671A3 (en) Anti-cd71 monoclonal antibodies and uses thereof for treating malignant tumour cells
WO2006065392A3 (en) Cancer treatments
WO2006076691A3 (en) Irta-2 antibodies and their uses
WO2008019326A3 (en) Ephb3-specific antibody and uses thereof
WO2007100920A3 (en) Diagnosis and treatment of prostate cancer
WO2009004496A3 (en) Bisanthrapyrazoles as anti-cancer agents
WO2008137128A3 (en) Methods of treating fungal infections
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
EP1868435A4 (en) Combinations, methods and compositions for treating cancer
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2008521751

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006272372

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006760894

Country of ref document: EP

Ref document number: 1020087004228

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2006272372

Country of ref document: AU

Date of ref document: 20060721

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006272372

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006760894

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11996270

Country of ref document: US